Immunovant, Inc. IMVT Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value

Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value at other companies

Merck & Co.MRK

——

Net income-$147.9M-38.9%

EPS (diluted)-$0.73-15.9%

Cash & equivalents$902.1M+26.4%

Total debt$72.0K-26.5%

Total equity$852.6M+20.5%

Total assets$957.0M+23.3%

Operating cash flow-$95.1M+14.1%

CapEx$8.0K-96.0%

Free cash flow-$95.1M+14.2%

Market cap$7.26B+74.2%

Enterprise value$6.35B+89.7%

Return on equity-64.8%+2.5pp

Debt / equity0×0.0×

Current ratio9.1×-2.1×

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1.

The official record: Immunovant, Inc.’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value?: Immunovant, Inc. (IMVT) reported share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value of $69.04M in Q4 2025.
How has Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value changed year-over-year?: Immunovant, Inc.'s share-based compensation arrangement by share-based payment award, options, exercisable, intrinsic value decreased by 52.3% year-over-year, from $144.88M to $69.04M.